Pomegra
Stockholm's Tandem Health closes a $100M Series B led by the EU-backed Scaleup Europe Fund to expand AI-native clinical tools across 14 European markets.
- The Scaleup Europe Fund, managed by EQT and targeting €5 billion, leads the round - its first investment in healthcare AI.
- Total Tandem funding reaches $160M, up from $50M after its 2025 Series A, tripling capitalization in roughly 12 months.
- Platform already serves more than 10,000 care organizations across 14 European national markets.
Lead
Stockholm-based Tandem Health raised $100 million in a Series B round on September 14, 2026, led by the Scaleup Europe Fund, a €5 billion vehicle managed by private equity firm EQT that blends public and private capital to back European deeptech, AI, and life sciences companies. Returning backers Kinnevik, Northzone, Amino Collective, and Visionaries Club all participated. Valuation was not disclosed.
What Does Tandem Actually Build?
The three-year-old company develops an AI-powered medical scribe that records clinical conversations and converts them into structured documentation, cutting the administrative load physicians carry after each patient encounter. The longer-term ambition runs further: Tandem is pitching an "AI-native clinic operating system" that would also manage patient flows and execute autonomous clinical tasks.
Whether the operating system framing holds up in practice is a reasonable question. Medical scribes occupy a crowded field. U.S.-based players including Nuance, and a string of well-funded startups, have been working the same documentation problem for years. Tandem's case is that it was designed from the start for European healthcare, employing roughly 100 in-house clinicians to tune its models for local clinical norms, reimbursement structures, and languages across its 14 national markets. That is an expensive and unusual choice for a software company, and it signals that clinical accuracy - not just raw model capability - is the bet.
Why Did the Scaleup Europe Fund Pick Healthcare Now?
This is the fund's first healthcare AI investment since it launched with a €5 billion target. European healthcare systems are under documented administrative strain: physician burnout and documentation backlogs have reached levels where hospital operators and governments are actively evaluating AI solutions rather than deferring to in-house IT. For a fund that mixes public capital with private, backing a company with 10,000 existing care organization clients is a lower-risk entry than a pre-revenue bet on clinical software.
The shape of the round also rewards scrutiny. Tandem closed a $50 million Series A in 2025, led by Kinnevik, with Northzone and others participating then too. A round twice the size arriving approximately 12 months later - without a valuation disclosure - suggests either that the company hit its milestones cleanly and needed capital to accelerate before consolidation, or that the competitive clock is running faster than originally planned. All prior investors returning is consistent with both readings.
What Does $100M Buy in European Healthcare AI?
The company plans to use the capital for customer base expansion, deeper localization, and the product shift toward the broader clinic operating system. With offices already operating in Germany, France, the UK, Spain, Italy, the Netherlands, Sweden, Finland, Norway, Denmark, Belgium, Portugal, Estonia, and Lithuania, significant geographic buildout is already done. The spending profile likely skews toward sales and engineering headcount - closing the gap between a documentation scribe and a platform that can justify the operating system pricing that investors are evidently expecting.
The in-house clinician headcount reinforces that story. Building proprietary clinical expertise into the product rather than relying entirely on general-purpose foundation models is a defensibility play. As larger technology companies sharpen their European healthcare focus, data quality and clinical trust may matter more than raw model benchmarks.
Outlook
Tandem enters late 2026 with the strongest funding position of any European-native clinical AI company, backed by a vehicle whose EU mandate gives it some cover in markets where public health authorities scrutinize data infrastructure ownership. The open question is whether Tandem can convert 10,000 users of a documentation tool into buyers of a full clinic operating system - a meaningfully different commercial motion that requires either renegotiated contracts or new buyers at a higher level of the healthcare organization. The $100 million buys time to find out.
